In the course of a 2-year combined chronic toxicity-carcinogenicity study performed according to Organisation for Economic Co-operation and Development (OECD) Test Guideline 453, systemic (blood cell) genotoxicity of two OECD representative nanomaterials, CeO 2 NM-212 and BaSO 4 upon 3-or 6-month inhalation exposure to rats was assessed. DNA effects were analysed in leukocytes using the alkaline Comet assay, gene mutations and chromosome aberrations were measured in erythrocytes using the flow cytometric Pig-a gene mutation assay and the micronucleus test (applying both microscopic and flow cytometric evaluation), respectively. Since nano-sized CeO 2 elicited lung effects at concentrations of 5 mg/m 3 (burdens of 0.5 mg/lung) in the preceding rangefinding study, whereas nano-sized BaSO 4 did not induce any effect, female rats were exposed to aerosol concentrations of 0.1 up to 3 mg/m 3 CeO 2 or 50 mg/m 3 BaSO 4 nanomaterials (6 h/day; 5 days/week; whole-body exposure). The blood of animals treated with clean air served as negative control, whereas blood samples from rats treated orally with three doses of 20 mg/kg body weight ethylnitrosourea at 24 h intervals were used as positive controls. As expected, ethylnitrosourea elicited significant genotoxicity in the alkaline Comet and Pig-a gene mutation assays and in the micronucleus test. By contrast, 3-and 6-month CeO 2 or BaSO 4 nanomaterial inhalation exposure did not elicit significant findings in any of the genotoxicity tests. The results demonstrate that subchronic inhalation exposure to different low doses of CeO 2 or to a high dose of BaSO 4 nanomaterials does not induce genotoxicity on the rat hematopoietic system at the DNA, gene or chromosome levels.
Introduction
Upon chronic inhalation exposure, respirable granular biodurable particles (GBPs) (1) , that are also called poorly soluble, low toxicity (PSLT) particles (2) , may potentially induce lung tumours in rats. Regardless of size, these particles appear to share the same mode-of-action (3) , and the apical toxic effects that nano-sized PSLT particles may elicit as compared to their larger sized counterparts will rather differ by severity than by the occurrence of inherently new effects specific to the nano-sized particles (1, 4) . Based on their intrinsic material properties and system-dependent properties that are dependent upon the respective in vitro, in vivo, or product-related environment, both CeO 2 and BaSO 4 nanomaterials are assumed to belong to the group of PSLT particles (5) (6) (7) (8) .
CeO 2 nanomaterials are being used in a broad variety of applications, such as solar cells, gas sensors, UV absorbents and silicon wafer polishing slurries (9, 10) . They have further been introduced into diesel fuel as additives to improve combustion processes, with resulting presence in emissions from vehicles using these fuels (11) .
In recognition of their economic significance, the Organisation for Economic Co-operation and Development (OECD) assigned CeO 2 nanomaterials a high priority for toxicological testing (12) (13) (14) . Due to their mechanical, optical and chemical properties, BaSO 4 nanomaterials are being used as fillers in coatings (e.g. in motor vehicles), and they are further considered suitable for medicinal application, e.g. as radiographic contrast media for diagnostic imaging or as bone cement additives in orthopaedics (15) (16) (17) .
CeO 2 and BaSO 4 nanomaterials differ in respect to their in vivo particle kinetics and pulmonary effects. A recent review addressing CeO 2 nanomaterial risk assessment came to the conclusion that translocation and biopersistence of this substance might pose longterm risks after prolonged exposure (18) . In short-term inhalation studies, CeO 2 nanomaterials revealed toxic potential on account of high particle retention, slow pulmonary clearance and the induction of pulmonary effects, such as (granulomatous) inflammation and granuloma formation (7, (19) (20) (21) . By contrast, BaSO 4 nanomaterials were found to have no or only very low toxicity with a remarkably fast pulmonary clearance upon short-term or sub-chronic inhalation even at high aerosol concentrations (8, 21, 22) .
The specific steps of the adverse-outcome-pathway of nano-sized PSLT particles [i.e. the process leading from the molecular initiating event to apical toxic effects (23) ] are still under discussion. Apart from pulmonary inflammation, oxidative stress and genotoxicity have been suggested to contribute to the formation of lung tumours after long-term inhalation exposure to PSLT nanoparticles (3, 24) . However, little is known about the specific long-term effects of airborne PSLT particles and, until now, only two PSLT nanomaterials (TiO 2 and carbon black) have been tested for tumour formation after 2-year inhalation exposure (25, 26) .
Similarly, in vivo inhalation studies investigating the potential genotoxicity of CeO 2 or BaSO 4 nanomaterials are scarce. The few available studies, which are in fact the range-finding studies to the present long-term study, do not report genotoxic properties of these two nanomaterials based on micronucleus test in rat peripheral blood cells (7, 8) . By contrast, in the more numerous in vitro studies available evaluating CeO 2 nanomaterial genotoxicity, DNA damage was observed in the Comet assay using different cell types including human dermal fibroblasts (27) , neuroblastoma cells (28) , human lymphoblastoid and Chinese hamster ovary cells (29) and mouse oocytes (30) . Similarly, chromosomal damage was observed in human dermal fibroblasts (31) and neuroblastoma cells (28) . No CeO 2 nanomaterial genotoxicity was recorded in the sister chromatid exchange and Comet assays using human lens epithelial cells (32) . Overall, the biological interactions of CeO 2 nanomaterials with cultured cells seem to be complex since also free radical-scavenging properties, such as antioxidant and anti-genotoxic effects, have been observed (33) . No in vitro genotoxicity of BaSO 4 NM-220 was recorded in the alkaline Comet assay performed with the reconstructed threedimensional human airway epithelial cell model EpiAirway™ (34) .
Generally, the relevance of the findings from in vitro genotoxicity studies for nanomaterial hazard assessment remains to be determined, and to date it is difficult, if not impossible, to reliably predict in vivo nanomaterial genotoxicity from the outcome of in vitro studies. Amongst other issues, such as the alignment of in vitro effective dosages to relevant in vivo aerosol concentrations (35, 36) , in vitro studies do not reflect the complexity of in vivo particle kinetics.
Upon inhalation exposure, CeO 2 nanomaterials were mainly deposited in the lung where they induced inflammatory responses (7, (37) (38) (39) . Pulmonary clearance appeared to be dose-dependently decreased, being decelerated at higher lung burdens (pulmonary retention half-times: 40 days at burdens of 40 µg/lung and >200 days at 2.62 mg/lung) (7). Upon intratracheal instillation, small fractions, i.e. <1% of the instilled CeO 2 nanomaterials (dose of around 250 µg/ lung), were absorbed and distributed into extra-pulmonary tissues, mainly in the liver (39) . After single or repeated inhalation exposure to aerosol concentrations of around 20 mg/m 3 CeO 2 NM-212, the test substance was detected in the liver, spleen, kidney, testis, epididymis and brain of rats (20) .
Against this background, a 2-year combined chronic toxicity and carcinogenicity inhalation study performed according to OECD Test Guideline (TG) 453 (40) , is being conducted to provide comprehensive information on PSLT nanomaterial long-term effects upon inhalation exposure. During this 2-year study, rats were exposed to aerosol concentrations of 0.1, 0.3, 1 or 3 mg/m 3 CeO 2 NM-212 or to 50 mg/m 3 of a reproduced batch of BaSO 4 NM-220 (in the following 'BaSO 4 NM-220'). These two nanomaterials were selected to represent different biokinetic properties within the group of PSLT nanomaterials. Dose-range findings, short term inhalation studies were conducted for the two nanomaterials, during which a noobserved-adverse effect concentration (NOAEC) of <0.5 mg/m 3 was determined for CeO 2 NM-212, whereas BaSO 4 NM-220 did not induce any effects at 50 mg/m 3 . These results have previously been published together with selected 3-month interim results of the long term study focusing on lung retention and pulmonary and systemic effects (7, 8) . Whereas evaluation and reporting of the findings from the 2-year exposure period were ongoing at the time of writing, the study at hand specifically summarises the results of the genotoxicity studies using blood cells of the rats after 3-and 6-month exposure to CeO 2 NM-212 or to BaSO 4 NM-220. Since blood sampling was undertaken in the course of the 2-year study, the outcome of the present genotoxicity study complements the broad spectrum of data collected within the framework of the long-term inhalation study.
Nanomaterials may induce DNA damage by different mechanisms leading to various types of genetic alterations. Therefore, a battery of tests covering different genotoxic mechanisms is best suitable to establish the genotoxic potential of nanomaterials (41, 42) . In the present study, three different test methods were applied to assess the genotoxicity of CeO 2 and BaSO 4 nanomaterials in rat blood cells at the DNA, gene and chromosomal levels. The alkaline Comet assay was performed to detect DNA strand breaks in nucleated leukocytes. Gene mutations induced in bone marrow erythrocyte precursor cells were assessed by the Pig-a gene mutation assay, which measures the frequency of CD59-negative reticulocytes (RETs) and total red blood cells (RBCs) indicative of glycosylphosphatidylinositol anchor deficiency caused by gene mutations at the phosphatidylinositol glycan-class A (Pig-a) locus. Encompassing flow cytometric analysis, it is an automated approach for the assessment of in vivo mutation frequencies. Therefore, it is suitable for routine testing, and it is finding increasing application in repeated-dose toxicity studies (43) (44) (45) . The induction of clastogenic and/or aneugenic alterations was assessed by the micronucleus test in peripheral RBCs applying both the classical microscopic and the automated flow cytometric scorings.
Materials and methods

Test substance characterisation
CeO 2 NM-212 was obtained from Umicore (Hanau, Germany). The BaSO 4 test material used in the present study was obtained from Solvay (Massa, Italy), as a reproduced batch of the original BaSO 4 NM-220. A comprehensive characterisation of the intrinsic material properties and system-dependent properties of CeO 2 NM-212 and BaSO 4 NM-220 has previously been published (7, 8, 46) . Likewise, the characterisation methodologies, the procedures for generation and characterisation of the aerosols as well as the inhalation system itself have previously been described (7, 8, 46, 47) .
(Of note, throughout the text, NM-x numbers refer to the respective numberings of the OECD representative nanomaterials coded in the list of the OECD Sponsorship Program for the Testing of Manufactured Nanomaterials; see http://www.oecd.org/ science/nanosafety/ and http://ihcp.jrc.ec.europa.eu/our_activities/ nanotechnology/nanomaterials-repository.)
Animals and study design
The inhalation study and all procedures on the living rats used therein were conducted at BASF SE, Experimental Toxicology and Ecology, Ludwigshafen, Germany. The animal study was approved by the local authorising agency for animal experiments (Landesuntersuchungsamt Koblenz, Germany) as referenced by the approval number G 12-3-028. Animals were housed in an AAALACaccredited facility in accordance with the German Animal Welfare Act and the effective European Council Directive. Five to seven weeks old female Wistar rats [strain: Crl:WI(Han)] were obtained from Charles River Laboratories (Sulzfeld, Germany). The rats were housed in groups of up to five animals in polysulfone cages (H-Temp (PSU); TECNIPLAST, Germany) with access to wooden gnawing blocks, GLP-certified feed (Kliba laboratory diet, ProvimiKliba SA, Kaiseraugst, Basel Switzerland), and water ad libitum under controlled conditions of temperature, humidity and light. The animals were acclimatised to the study conditions in the whole-body inhalation chambers by exposure to fresh air for 2 days (6 h, each) before the onset of the test substance exposure period.
The inhalation study, as a part of which the present genotoxicity studies were performed, was conducted as 2-year study according to OECD TG 453 (40) under good laboratory practice conditions. Animals were exposed to aerosol concentrations of 0.1, 0.3, 1 or 3 mg/ m 3 CeO 2 NM-212 or 50 mg/m 3 BaSO 4 NM-220 for 6 h/day (wholebody exposure) on 5 consecutive days/week (working days, only). Concordantly, a control group was exposed to clean, filtered air. During the hours of exposure, animals were not granted access to feed or drink. On exposure days, each animal was inspected clinically once after the exposure period. Occurrence of mortality was monitored twice daily on working days and once daily on weekends and holidays.
Blood sampling
For the genotoxicity studies, blood was collected from at least five animals per group after 3-and 6-month test substance exposure. Blood sampling was performed 24 h after the last exposure by retro-orbital venous plexus puncture under isoflurane anaesthesia (Isoba®, Essex GmbH, Munich, Germany). The blood samples were placed into K 2 EDTA tubes (Becton Dickinson, San José, CA, USA) and immediately shipped refrigerated (2-8°C) to the ENEA Laboratories (Italian National Agency for New Technologies, Energy and Sustainable Economic Development) Centro Ricerche Casaccia (Rome, Italy) for analysis.
Of the samples from the 3-month exposure groups, all BaSO 4 NM-220 samples and the 3 mg/m 3 CeO 2 NM-212 samples, as well as two samples, each, from the negative controls and the 1 mg/m 3 CeO 2 NM-212 group clotted during the shipment and therefore could not be analysed.
Alkaline Comet assay
Within 24 h after sampling, 30 µl of peripheral blood were used to perform the Comet assay as described by Singh et al. (48) with minor modifications. Briefly, blood was mixed with 0.7% (w/v) low-melting point agarose and sandwiched on microscope slides between a bottom layer of 1% (w/v) normal-melting point agarose and a top layer of 0.7% (w/v) low-melting point agarose (both agarose types: Bio-Rad Laboratories, Hercules, CA, USA). The slides were immersed overnight at 4°C in a lysing solution (2.5 M NaCl, 100 mM Na 2 EDTA, 10 mM Tris; pH 10) containing 10% DMSO and 1% Triton X-100. Upon completion of the lysis step, the slides were placed in a horizontal electrophoresis tank with fresh alkaline electrophoresis buffer (300 mM NaOH, 1 mM Na 2 EDTA; pH >13) and retained in the solution for 25 min at 4°C to allow for DNA unwinding and expression of the alkali-labile sites. Electrophoresis was carried out at 4°C for 25 min [27 V (1 V/cm) and 300 mA] using a Hoefer power supply (Pharmacia Biotec, Inc., San Francisco, CA, USA). After electrophoresis, slides were neutralised in 0.4 M Tris (pH 7.4) and fixed in absolute ethanol. Slides were air-dried at room temperature. Immediately before scoring, slides were stained with 12 µg/ml ethidium bromide (Sigma-Aldrich, St. Louis, MO, USA) and examined with an Olympus fluorescence microscope. Slides were analysed by a computerised image analysis system (Delta Sistemi, Rome, Italy). A total of one hundred cells, from two different slides were scored for each animal. DNA damage was recorded as the percentage of total DNA in the Comet tail (% tail intensity).
Pig-a gene mutation assay
Within 72 h after sampling, peripheral blood was processed according to the procedures described in the MutaFlowPLUS Kit® (Rat Blood; Litron Laboratories, Rochester, NY, USA) and as described by Dertinger et al. (49) . Approximately 80 μl of blood were mixed with 100 μl of anticoagulant solution. Most leukocytes and platelets were depleted by density-gradient centrifugation with LympholyteMammal solution (Cedarlane, Burlington, NC) and the resulting erythrocyte-enriched samples were labelled with phycoerythrin (PE)-anti-CD59 and PE-anti-CD61 (from the MutaFlow kit), followed by labelling with anti-PE magnetic microbeads (Miltenyi Biotech, Auburn, CA, USA). After washing, cells were mixed with 1 ml buffer solution. A small fraction of the labelled cells and beads suspension was reserved as a 'pre-column' sample for subsequent flow cytometric analysis. The main part of the labelled cells and beads suspension was processed on an LS magnetic column (Miltenyi) mounted onto a quadroMACS magnet (Miltenyi). CD59-positive wild-type RBCs, and CD61-positive platelets were retained on the column and the flow through fraction, consisting of enriched CD59-deficient (Pig-a mutant) RBCs, was collected as a 'post-column' sample for subsequent flow cytometric analysis. Before the analyses, both the 'pre-' and 'post-column' samples were stained with a solution containing SYTO13® dye (from the MutaFlow kit) and CountBright™ absolute counting beads (Life Technologies, Carlsbad, CA, USA).
An instrument calibration standard was prepared by creating a specimen consisting of ~ 50% wild-type and 50% mutant-mimicking cells processed in the same way as the experimental samples but not incubated with antibodies. The flow cytometric analysis was performed on a FACSCalibur flow cytometer (Becton Dickinson) equipped with a 488 laser. For each animal, the frequencies of Pig-a mutant RBCs and RETs were calculated from the cell equivalents analysed using the ratios of the CountBright beads to total RBCs and RETs in the 'pre-column' sample and the ratios of CountBright beads to enriched mutant total RBCs and mutant RETs in the 'postcolumn' sample. Additionally, the percentage of RETs (%RETs), identified as SYTO® 13 positive cells, was recorded as an index for cytotoxicity with reduced %RET indicating cytotoxicity.
Micronucleus test
Microscopic analysis Acridine Orange (AO) was dissolved in distilled water at a concentration of 1 mg/ml. Pre-heated cleaned glass slides were stained with 5 µl of this solution, and 5 µl of peripheral blood were placed in the centre of AO-stained slides, covered with a coverslip and gently pressed. Slides were stored at +4°C and analysed within a few days. Two slides, 1000 RETs per slide, were analysed for each animal using a fluorescence microscope.
Flow cytometric analysis
Peripheral blood was processed according to the procedure described in the Rat Blood MicroFlow Micronucleus Analysis Kit® (Litron Laboratories). Briefly, within 24 h from sampling, 30 µl blood were mixed with 175 µl anticoagulant solution and 180 µl of this suspension were immediately fixed in ultra-cold methanol and stored at −80°C. Prior to analysis, samples were washed and incubated with RNase, anti-CD71-FITC (anti-transferrin receptor antibody that labels RETs), and anti-CD61-PE (anti-platelet antibody that labels platelets) for 30 min at 4°C followed by 30 min at room temperature. Immediately before analysis, the samples were re-suspended in an appropriate amount of kit-supplied DNA staining solution. The flow cytometer photomultiplier and compensation tubes were adjusted using a kit-supplied malaria-infested blood sample. This biological standard was used to set the optimal voltage for resolving parasitised (micronucleus-like) RETs, and hence the position of the quadrant delineating normochromatic RBCs and RETs with and without micronuclei. The samples were analysed on a Becton Dickinson FACSCalibur flow cytometer using the CellQuest software (Becton Dickinson, Franklin Lakes, NJ, USA). Twenty thousand RETs were analysed per blood sample. Again, the %RETs, identified as CD-71 positive cells, was recorded as an index for cytotoxicity.
Positive control group
N-ethyl-N-nitrosourea (ENU; CAS No. 759-73-9; Sigma-Aldrich) dissolved in phosphate buffered saline (pH 6.1) at a volume of 10 ml/kg body weight (b.w.) was used as positive control. Five 7-week old female Wistar rats were treated orally by gavage with three doses of 20 mg/kg b.w. ENU separated by 24 h. Before the treatment, blood samples were collected from the rats' tail veins for use as matched controls. The alkaline Comet assay and the micronucleus test were conducted on blood sampled 4 days after the first administration and the Pig-a gene mutation assay on blood sampled 30 days after the onset of administration.
Statistical analysis
Mean values and standard errors were calculated from the data recorded for the individual animals of each group. Statistical analysis was performed using the STATISTICA software (StatSoft, Inc., Tulsa, OK, USA). Comparison among group means was performed by one-way ANOVA and Dunnett's test was used for post hoc comparison of treatments to controls. The paired Student's t-test was applied to analyse the data obtained before and after treatment with ENU. Findings were assessed as treatment-related when their probability level was lower than 5% (P < 0.05).
Results
Clinical observation
During the 6 months of inhalation exposure recorded for the present study, treatment-related clinical signs were not observed in any of the rats.
Genotoxicity assays
The known mutagen ENU used to test the proficiency of the laboratory and the sensitivity of the test systems consistently provided positive results in all three genotoxicity tests. In the alkaline Comet assay, ENU treatment elicited a significant (P < 0.001) increase in DNA damage ( Figure 1A ). In the Pig-a gene mutation assay, mutation frequencies were significantly (P < 0.001) increased in RBCs and RETs 30 days after the onset of ENU administration (Figure 2A ). In the micronucleus test, the percentage of micronucleated RETs was significantly (P < 0.001) increased on Day 4 after the onset of ENU administration as assessed microscopically and by flow cytometry with both evaluation techniques providing similar numerical results ( Figure 3A) . By flow cytometric analysis, the RET% was decreased in the blood samples collected 4 days after the onset of ENU administration which further reflected the cytotoxic effect of this positive control ( Figure 3B ). The data of ENU administration demonstrate clearly the proficiency of the laboratory. Table S1 , available at Mutagenesis Online.
The comet assay vehicle control values were slightly higher than the historical control value of the laboratory which can be likely explained by the 24-h shipment interval between sampling and slide preparation. No statistically significant increase of DNA damage over the concurrent vehicle controls was induced by inhalation exposure to CeO 2 NM-212 or BaSO 4 NM-220 (Figures 1B and C for the 3-and 6-month exposure durations, respectively).
In the Pig-a gene mutation assay, the frequency of mutant RBCs and RETs remained unaltered after 3-or 6-month exposure to the mentioned concentrations of CeO 2 NM-212 or BaSO 4 NM-220 ( Figure 2B and D for the 3-and 6-month exposure groups, respectively). Among all CeO 2 -exposed rats, only one animal of the 0.3 mg/ m 3 6-month exposure group showed an exceedingly high mutant RBC value that was 2-3 orders of magnitude higher than the mean value of the other animals in the same group. This value was considered an extreme outlier and therefore excluded from the calculation of the respective group mean. Two other not-so-extreme outliers were noticed in the 1 mg/m 3 CeO 2 3-month and vehicle control 6-month groups that had some impact on the respective group mean and standard deviation values. In these cases, the statistical analysis was carried out without removing their values from their group. Anyhow, in all cases, the outcome of the statistical comparison between treated and control groups would not have changed irrespectively of the inclusion or exclusion of the outliers. Noteworthy, in the phenotype-based Pig-a mutation assay it is not possible to determine whether the high mutant frequency in a single individual of a group is due to many independent mutation events or to a single mutation event occurred in a hematopoietic stem cell followed by the mutant clone expansion.
Finally, also the RET% remained unchanged after exposure to CeO 2 NM-212 or BaSO 4 NM-220 thereby providing an indication that these nanomaterials do not elicit cytotoxic effects in RBC precursors ( Figure 2C and E for the 3-and 6-month exposure groups, respectively).
In the micronucleus test, 3-month exposure to 0.1-1 mg/m 3 CeO 2 NM-212 did not elicit an increase in the percentage of micronucleated RETs as analysed by microscopy ( Figure 3C ). Also after 6-month exposure to 0.1-3 mg/m 3 CeO 2 NM-212 or 50 mg/m 3 BaSO 4 NM-220, the frequency of micronucleated RETs remained unaltered, with the microscopic and flow cytometric evaluations again providing consistent results ( Figure 3D ). The flow cytometric assessment of the RET%, identified by CD71 antibody labelling ( Figure 3E ), indicated that CeO 2 NM-212 or BaSO 4 NM-220 exposure further did not induce cytotoxic effects in RETs, which was consistent with the results obtained by SYTO® 13 labelling in the Pig-a gene mutation assay ( Figure 2E ).
Discussion
An increasing number of in vitro genotoxicity studies assessing a variety of nanomaterials is being published, but only relatively few report corresponding in vivo studies. Reviews of published genotoxicity studies concluded that findings are inconsistent for most nanomaterials and that a definite conclusion on their genotoxic potential has not yet been possible (42, 50) . Moreover, very little is known about apical toxic effects that nanomaterials may elicit as a result of genotoxic events. Within the available, published studies, only two nanomaterials (i.e. TiO 2 and carbon black) have actually been tested for their carcinogenic potential upon inhalation exposure, and in both studies the rats were treated with single, high aerosol concentrations (25, 26) . The mechanisms which led to the formation of the lung tumours observed in these studies are still under debate (1, (51) (52) (53) (54) (55) (56) as is the potential of nanomaterials to cause primary or secondary genotoxic lesions in the lung (50). To contribute to closing this knowledge gap, two OECD representative nanomaterials, CeO 2 NM-212 and BaSO 4 NM-220, have been assessed in a long-term rat inhalation study performed in accordance with OECD TG 453 (40) . This long-term study has specifically been designed to reveal possible local carcinogenic effects in the lung, as well as tumours in extra-pulmonary tissues or other long-term effects that the two test substances might elicit (57, 58) . The present genotoxicity study was performed as a part of this long-term study, with the results of the 2-year exposure period still being under evaluation at the time of writing this publication. In the present study, neither 3-or 6-month inhalation exposure to 0.1 up to 3 mg/m 3 CeO 2 NM-212 or 50 mg/m 3 BaSO 4 NM-220 induced systemic (rat blood cell) genotoxicity as investigated in the alkaline Comet assay, the Pig-a gene mutation assay, and the micronucleus test, addressing the DNA, gene and chromosomal levels, respectively.
Extra-pulmonary bioavailability of inhaled nanomaterials
Against this background, this section of the discussion addresses the question whether the CeO 2 and BaSO 4 nanomaterials did not cause peripheral blood cell genotoxicity because they did not reach the target organs bone marrow and blood in the first place or whether the outcome of the present study provides an indication of the lack of rat blood cell genotoxicity of these substances.
Generally, inhaled PSLT particles may translocate from the lung to extra-pulmonary organs (59), but, as a rule, translocation seems to be low (below 10% by mass) (60, 61) . If inhaled PSLT particles are deposited or retained in extra-pulmonary organs, the occurrence of systemic adverse effects seems to be rare, and it is most likely of low relevance for hazard assessment (61) . However, one type of nano-sized PSLT particles, i.e. carbon black, has been observed to elicit oxidative stress and genotoxic effects in the epithelial cells of the lung after chronic inhalation exposure to rats (25) . This raised the question whether the genotoxic potential of carbon black might result in lung tumour formation. Further, it was asked whether the carcinogenic mechanism might not be restricted to the lung tissue, but might also involve extra-pulmonary organs in case the test substance translocates and deposition in secondary organs occurs (45,55). More recently, the pulmonary clearance and biodistribution of CeO 2 NM-212 or BaSO 4 NM-220 have been assessed both after intratracheal instillation (8, 39) and inhalation exposure (7, 20) . Twenty-eight days after a single intratracheal instillation of 1 mg/kg b.w. CeO 2 NM-212 (corresponding to approximately 0.25 mg/lung), 88% of the dose remained in the lungs and <1% was found in extrapulmonary organs, mainly in the liver and bones (39) . The rest was excreted in the faeces and urine. By contrast, 28 days after a single intratracheal instillation of 0.28 mg/lung BaSO 4 NM-220, 16% of the dose remained in the lungs (8) , and 29% of the instilled dose was found in the bones and 7% in the remaining organs. The rest was excreted in the faeces and urine. In both studies, 0.078% and 6.87% of the initially instilled doses of CeO 2 and BaSO 4 , respectively, were retained in the bone marrow 28 days after test substance administration (8, 39) , with the bone marrow being the hematopoietic target organ for possible micronucleus and Pig-a gene mutation induction.
Also after inhalation exposure, CeO 2 translocation from the lung to extra-pulmonary organs has been demonstrated, both in rats (7, 20) and mice (37) . Four-week exposure to 25 mg/m 3 CeO 2 NM-212 resulted in a rat lung burden of ~2.6 mg/lung. Additionally, the test material was found in the liver, but only at low concentrations, with the liver burden [assessed by inductively coupled plasmamass spectrometry (ICP-MS)] being <2 µg both on Day 3 after the final exposure as well as after the 8-week post-exposure period (7). However, even though CeO 2 NM-212 was present in the liver, its histopathologic assessment revealed no morphological changes (7).
Hence, CeO 2 NM-212 may indeed be biodistributed to extra-pulmonary organs upon inhalation exposure to realistic concentrations (as compared to the high bolus doses applied during intratracheal instillation), but this biodistribution appears to have low-or noimpact on systemic toxicity. Although the specific deposition and retention rates of CeO 2 and BaSO 4 nanomaterials in the bones and bone marrow were not observed in the respective short-term and longterm inhalation studies, the available biodistribution data suggest that the two nanomaterials may also reach these tissues upon inhalation exposure, which is consistent with the findings after intratracheal instillation. Similarly, an earlier study revealed that 40 mg/m 3 inhaled micron-sized BaSO 4 (particle size 1-2 µm) translocated from the lung to the bone and was incorporated into the bone (62) .
In the rats used in the present study, 3-month inhalation exposure to 0.1 and 3 mg/m 3 CeO 2 NM-212 or 50 mg/m 3 BaSO 4 NM-220 resulted in CeO 2 lung burdens of 0.012 ± 0.003 and 1.4 ± 0.2 mg/ rat lung, respectively, and a BaSO 4 burden of 1.7 ± 0.9 mg/rat lung (assessed by ICP-MS) (8, 63) . Translocation to the tracheobronchial and mediastinal lymph nodes was recorded, but at low levels of 0.5% and 1.9% of the BaSO 4 and CeO 2 lung burdens, respectively. After 3-month exposure to CeO 2 or BaSO 4 , clinical observations, haematology, clinical chemistry or the determination of acute phase proteins in the blood provided no indications for the evolvement of systemic effects (data not published). Likewise, no or only very low systemic toxicity of the two nanomaterials was observed after 1-or 4-week exposure to even higher lung burdens and aerosol concentrations of up to 25 mg/m 3 CeO 2 . Hence, all available intratracheal instillation or inhalation studies consistently report extra-pulmonary tissue distribution of CeO 2 or BaSO 4 nanomaterials, but only minor systemic apical toxic effects.
In vivo genotoxicity studies
Finally, the capacity of the genotoxicity assays used in the present study to detect different kinds of genetic alterations remains to be addressed, just as the negative outcome of all tested endpoints (DNA damage, Pig-a gene mutation, micronucleus formation) is to be placed into the context of published in vivo studies addressing the genotoxicity of CeO 2 or BaSO 4 nanomaterials. Each applied genotoxicity test demonstrated to be able to detect the specific DNA alteration induced by oral administration of the positive control ENU to rats. Additionally, the micronucleus test provided consistent results regardless of whether the microscopic or flow cytometric technique was used for scoring.
Treatment by gavage of rats with a single high dose of 1000 mg/ kg b.w. CeO 2 nanomaterial or 28-day oral treatment with 600 mg/kg b.w./day (size: 23 nm by transmission electron microscopy; 190 nm in water by dynamic light scattering), induced significant increases of DNA damage in peripheral blood leucocytes and hepatocytes, micronuclei in bone marrow and blood cells, and chromosomal aberrations in bone marrow cells (64, 65) . The Authors concluded that these effects might be attributable to oxidative stress reactions.
By contrast, upon 1-or 4-week inhalation exposure to aerosol concentrations of up to 25 mg/m 3 CeO 2 or 50 mg/m 3 BaSO 4 , no systemic genotoxicity was observed in the micronucleus test assessing rat peripheral blood cells, even though particle translocation from the lung to the liver was observed (7) . Similarly, 4-week inhalation exposure of rats to 50 mg/m 3 BaSO 4 NM-220 did not induce an increase of micronucleated RBCs (8) . These works by Keller and co-workers as well as Konduru and co-workers were the range finding studies to the 2-year study of which the present study is a part, and all studies applied the same test substances, i.e. CeO 2 NM-212 and a reproduced batch of BaSO 4 NM-220.
In summary, the results of the present study, reporting no genotoxicity of 3-or 6-month inhalation exposure to aerosol concentrations up to 3 mg/m 3 CeO 2 NM-212 or 50 mg/m 3 BaSO 4 NM-220 either on the DNA, gene or chromosome levels, stand in agreement with the negative outcome of the micronucleus test using RBCs upon 4-week inhalation exposure to up to 25 mg/m 3 CeO 2 NM-212 (7) or 50 mg/m 3 BaSO 4 NM-220 (8) . A quantitative comparison of the target doses obtained in all of these inhalation studies with those reached in the oral genotoxicity studies reported by Kumari et al. (64, 65) -let alone with the effective dosages of the in vitro genotoxicity studies summarised in the introduction section-may only be performed with a too great level of uncertainty to allow for a meaningful interpretation of the different outcomes of these studies.
Conclusion
Generally, the CeO 2 or BaSO 4 lung burden and nanomaterial translocation elicited in the present study seems to be either too low to elicit oxidative stress-induced genotoxicity, or the two nanomaterials may not bear genotoxic potential under the experimental conditions of the present study. The four different aerosol concentrations of CeO 2 NM-212 used in the long-term inhalation study [ 
